KR20100012089A - 경상이성체성 순수 에스시탈로프람의 용도 - Google Patents

경상이성체성 순수 에스시탈로프람의 용도 Download PDF

Info

Publication number
KR20100012089A
KR20100012089A KR1020097027003A KR20097027003A KR20100012089A KR 20100012089 A KR20100012089 A KR 20100012089A KR 1020097027003 A KR1020097027003 A KR 1020097027003A KR 20097027003 A KR20097027003 A KR 20097027003A KR 20100012089 A KR20100012089 A KR 20100012089A
Authority
KR
South Korea
Prior art keywords
disorders
escitalopram
treatment
citalopram
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097027003A
Other languages
English (en)
Korean (ko)
Inventor
코니 산케스
옌센 예스페르 링
아르네 뫼르크
Original Assignee
하. 룬트벡 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하. 룬트벡 아크티에 셀스카브 filed Critical 하. 룬트벡 아크티에 셀스카브
Publication of KR20100012089A publication Critical patent/KR20100012089A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020097027003A 2001-05-01 2002-05-01 경상이성체성 순수 에스시탈로프람의 용도 Ceased KR20100012089A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100684 2001-05-01
DKPA200100684 2001-05-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7014286A Division KR20040030609A (ko) 2001-05-01 2002-05-01 경상이성체성 순수 에스시탈로프람의 용도

Publications (1)

Publication Number Publication Date
KR20100012089A true KR20100012089A (ko) 2010-02-05

Family

ID=8160464

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097027003A Ceased KR20100012089A (ko) 2001-05-01 2002-05-01 경상이성체성 순수 에스시탈로프람의 용도
KR10-2003-7014286A Ceased KR20040030609A (ko) 2001-05-01 2002-05-01 경상이성체성 순수 에스시탈로프람의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR10-2003-7014286A Ceased KR20040030609A (ko) 2001-05-01 2002-05-01 경상이성체성 순수 에스시탈로프람의 용도

Country Status (25)

Country Link
US (7) US20040198809A1 (https=)
EP (1) EP1385503A1 (https=)
JP (1) JP2004527551A (https=)
KR (2) KR20100012089A (https=)
CN (1) CN1509169A (https=)
AR (1) AR033308A1 (https=)
AT (1) AT10974U1 (https=)
BG (1) BG108379A (https=)
BR (1) BR0208283A (https=)
CA (1) CA2445843A1 (https=)
CZ (1) CZ20033267A3 (https=)
EA (1) EA200301195A1 (https=)
HR (1) HRP20030744A2 (https=)
HU (1) HUP0400054A3 (https=)
IL (1) IL158031A0 (https=)
IS (1) IS6954A (https=)
ME (1) MEP5908A (https=)
MX (1) MXPA03008777A (https=)
NO (1) NO20034538D0 (https=)
PL (1) PL367480A1 (https=)
SK (1) SK14612003A3 (https=)
UA (1) UA82828C2 (https=)
WO (1) WO2002087566A1 (https=)
YU (1) YU85303A (https=)
ZA (1) ZA200307102B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
AU2003287919B2 (en) * 2002-12-23 2009-11-12 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
PL1691811T3 (pl) * 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005084643A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
EA200801081A1 (ru) 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
JP2009511607A (ja) * 2005-10-14 2009-03-19 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
CN100353939C (zh) * 2006-01-05 2007-12-12 昆明积大制药有限公司 含西酞普兰和环糊精的抗抑郁口服药用组合物
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
CA2672925A1 (en) * 2006-10-20 2008-04-24 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
US20100003313A1 (en) * 2006-10-27 2010-01-07 Hisamitsu Pharmaceutical Co.,Inc. Adhesive skin patch
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
US20090036468A1 (en) * 2007-08-03 2009-02-05 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
SG185969A1 (en) * 2008-01-31 2012-12-28 Takeda Pharmaceutical Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
US10702512B2 (en) * 2015-05-13 2020-07-07 A. Carlsson Research Ab Treatment of debilitating fatigue

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (https=) * 1965-03-18
US4079135A (en) * 1973-12-13 1978-03-14 Imperial Chemical Industries Limited Morpholine derivatives as antidepressants
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
EA002770B1 (ru) * 1997-11-11 2002-08-29 Х.Лундбекк А/С Способ получения циталопрама
AU4850199A (en) * 1998-06-30 2000-01-17 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
PL199423B1 (pl) * 1998-10-20 2008-09-30 Lundbeck & Co As H Sposób wytwarzania citalopramu
DK1173431T4 (da) * 1999-04-14 2010-01-04 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6469064B2 (en) * 2000-04-24 2002-10-22 Aryx Therapeutics Materials and methods for the treatment of depression
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram

Also Published As

Publication number Publication date
NO20034538L (no) 2003-10-09
ZA200307102B (en) 2004-09-13
AT10974U1 (de) 2010-02-15
HUP0400054A2 (hu) 2004-04-28
BR0208283A (pt) 2004-03-09
AR033308A1 (es) 2003-12-10
US20040198811A1 (en) 2004-10-07
US20040192766A1 (en) 2004-09-30
US20040192765A1 (en) 2004-09-30
CA2445843A1 (en) 2002-11-07
US20080004338A1 (en) 2008-01-03
KR20040030609A (ko) 2004-04-09
EA200301195A1 (ru) 2004-04-29
IL158031A0 (en) 2004-03-28
WO2002087566A1 (en) 2002-11-07
HUP0400054A3 (en) 2007-03-28
CZ20033267A3 (en) 2004-06-16
BG108379A (bg) 2004-11-30
EP1385503A1 (en) 2004-02-04
US20040192764A1 (en) 2004-09-30
MEP5908A (xx) 2010-02-10
PL367480A1 (en) 2005-02-21
IS6954A (is) 2003-09-15
UA82828C2 (en) 2008-05-26
US20040198809A1 (en) 2004-10-07
US20040198810A1 (en) 2004-10-07
YU85303A (sh) 2006-05-25
SK14612003A3 (sk) 2004-04-06
MXPA03008777A (es) 2004-02-12
JP2004527551A (ja) 2004-09-09
HRP20030744A2 (en) 2005-06-30
CN1509169A (zh) 2004-06-30
NO20034538D0 (no) 2003-10-09

Similar Documents

Publication Publication Date Title
KR20100012089A (ko) 경상이성체성 순수 에스시탈로프람의 용도
MXPA04011762A (es) Una combinacion de antagonista de nmda e inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
AU2007253684A1 (en) Treatment for depressive disorders
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6387956B1 (en) Methods of treating obsessive-compulsive spectrum disorders
KR20120124423A (ko) 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
AU2682500A (en) Topic tricyclic antidepressants as analgesics
Ng et al. Venlafaxine and bilateral acute angle closure glaucoma
Nelson et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163)
Bystritsky et al. Pilot open‐label study of nefazodone in panic disorder
de Oliveira et al. Melatonin as an adjunctive treatment on dental procedures: A systematic review
WO2008035177A2 (en) Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor
AU2002254870A1 (en) The use of enantiomeric pure escitalopram
AU2008201217A1 (en) The use of enantiomeric pure escitalopram
HK1067047A (en) The use of enantiomeric pure escitalopram
HRP20100463A2 (hr) Upotreba čistog enantiomernog citaloprama
US20250241933A1 (en) Methods of treating sleep apnea with a combination of a cannabinoid and a carbonic anhydrase inhibitor
Amsterdam et al. Once-versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study
JP2007513095A5 (https=)
WO2003072093A1 (en) METHOD OF TREATMENT OF HYPERTENSION USING SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRIs)
Dodd et al. Duloxetine for major depression
Wade et al. Escitalopram 10 mg/day is an effective and well-tolerated first-line antidepressant in primary care
MX2014002965A (es) Combinaciones que comprenden un modulador del receptor de s1p.
Hesselmann et al. P. 1.054 Combined antidepressant therapy using mirtazapine and citalopram in therapy resistent depression

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20091224

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100121

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100421

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20101025

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100421

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I